Clinical Trial Update: Post Trial Access Program of TAK-577 for Von Willebrand Disease (VWD)

View source ↗

Summary

Updates on the post-trial access program for TAK-577 in patients with Von Willebrand disease, outlining continued access after participation in the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Willebrand Disease

Drugs mentioned

• TAK-577

Snippet

Sponsor: Takeda | Conditions: Von Willebrand Disease (VWD) | Status: AVAILABLE